SCHEMBL2235560

SCHEMBL2235560

COC(=O)NNc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.59
POLB P06746 1/20 0.53
RAB9A P51151 9/20 0.53
NPC1 O15118 7/20 0.53
SMN1; SMN2 Q16637 4/20 0.50
GFER P55789 1/20 0.50
P2RX7 Q99572 1/20 0.49
ALDH1A1 P00352 3/20 0.47
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365913 0.83 GAA (0.53) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL513736 0.81 RAB9A (0.64) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL20984862 0.80 GAA (0.67) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2233791 0.78 GAA (0.60) GAAPOLBSMN1; SMN2ALDH1A1KMT2A
SCHEMBL20711459 0.74 GAA (0.59) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL7608124 0.74 GAA (1.00) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL20711454 0.73 GAA (0.57) GAAPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL2233433 0.72 GAA (0.67) GAASMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL30912304 0.72 RAB9A (0.54) GAAPOLBRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL28201063 0.71 GAA (0.65) GAASMN1; SMN2ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102186811-B Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CO LTD 2013-07-24 CN disclosed
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
CN-102186811-A Process for producing bisoxazolinone compound and intermediate thereof SUMITOMO CHEMICAL CO 2011-09-14 CN disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR GAA 4157/4885POLB 2483/4885RAB9A 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.